The List’s annual revision process is led by WADA, beginning with an initial meeting in January and concluding with the publication of the List by 1 October. This is an extensive consultation process that includes WADA’s List Expert Groupgathering information, circulating a draft List among stakeholders, taking their submissions into consideration and revising the draft, followed by review by the Agency’s Health, Medical and Research (HMR) Committee.
The HMR Committee then makes its recommendation to the WADA Executive Committee, which approves the List during its September meeting.
For a substance or method to be added to the List, it must be determined that it meets two of the following three criteria:
It has the potential to enhance or enhances sport performance
It represents an actual or potential health risk to the athletes
It violates the spirit of sport
It should be noted that for athletes who have a legitimate medical reason for using a prohibited substance or method that is on the List, they may be accommodated if they meet the criteria outlined in the International Standard for Therapeutic Use Exemptions (ISTUE). The TUE process has overwhelming acceptance from athletes, physicians and anti-doping stakeholders worldwide.
Stakeholders wishing to translate the List into other languages are kindly asked to signal their interest to firstname.lastname@example.org. If interested, WADA would provide the necessary files and, once the translation is finalized, would make the List available on the Agency’s website.